On August 6, TRANSTHERA-B rose 5.08% in regular trading, trading at HKD 12.2/share, with turnover of HKD 48.85 million, extending its recent strong rebound momentum.

On the news front, the company has been conducting intensive H-share buybacks since July, accumulating 718,000 shares repurchased at a total cost exceeding HKD 7 million, signaling management confidence in the company's intrinsic value. Additionally, on July 24, the company granted approximately 5.259 million H-share incentives to 67 employees, including 2.817 million share awards and 2.442 million share options, further aligning core team interests with shareholders.

On the pipeline front, the company's core product Tinengotinib has completed enrollment for its global registrational Phase III clinical trial for advanced cholangiocarcinoma. Meanwhile, TT-00973 received approval on July 10 for a Phase II trial combining with furmonertinib for EGFR-mutant NSCLC, and TT-01488 was approved on July 1 for a Phase II trial in mantle cell lymphoma in combination with anti-CD20 monoclonal antibody regimens. The multi-pipeline advancement has bolstered market expectations for the company's development trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)